Maryam Taghizadeh-Ghehi

Maryam Taghizadeh-Ghehi

Auto-generated profile, based on publicly available information

Maryam Taghizadeh-Ghehi

Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2008 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
MHM Hadjibabaie
M Hadjibabaie
MIM Iravani
M Iravani
MTM Taghizadeh
M Taghizadeh
AAA Ataie-Jafari
A Ataie-Jafari
ASAhmad Reza Shamshiri
Ahmad Reza Shamshiri
AGA Ghavamzadeh
A Ghavamzadeh

15 November 2016 in Drug Safety
Verified
Journal Article
Closed access
PDF file
MMMehdi Mohammadi
Mehdi Mohammadi
ZJZahra Jahangard-Rafsanjani
Zahra Jahangard-Rafsanjani
ASAmir Sarayani
Amir Sarayani
MHMolouk Hadjibabaei
Molouk Hadjibabaei
MTMaryam Taghizadeh-Ghehi
Maryam Taghizadeh-Ghehi

10 March 2014 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
AMA Moslehi
A Moslehi
MTM Taghizadeh-Ghehi
M Taghizadeh-Ghehi
KGK Gholami
K Gholami
MHM Hadjibabaie
M Hadjibabaie
ZJZ Jahangard-Rafsanjani
Z Jahangard-Rafsanjani
AGA Ghavamzadeh
A Ghavamzadeh

6 May 2015 in Renal Failure
Verified
Journal Article
Closed access
PDF file
MTMaryam Taghizadeh-Ghehi
Maryam Taghizadeh-Ghehi
ASAmir Sarayani
Amir Sarayani
AAAsieh Ashouri
Asieh Ashouri
SASara Ataei
Sara Ataei
AMAmirhossein Moslehi
Amirhossein Moslehi
MHMolouk Hadjibabaie
Molouk Hadjibabaie
Acute kidney injury (AKI) is common in hematopoietic stem cell transplantation (HSCT) patients with an incidence of 21–73%. Prevention and early diagnosis reduces the frequency and severity of this complication. Predictive biomarkers are of major importance to timely diagnosis. Neutrophil gelatinase associated lipocalin (NGAL) is a widely investigated novel biomarker for early diagnosis of AKI. However, no study assessed NGAL for AKI diagnosis in HSCT patients. We performed further analyses on gathered data from our recent trial to evaluate the performance of urine NGAL (uNGAL) as an indicator of AKI in 72 allogeneic HSCT patients. AKI diagnosis and severity were assessed using Risk–Injury–Failure–Loss–End-stage renal disease and AKI Network criteria. We assessed uNGAL on days −6, −3, +3, +9 and +15. Time-dependant Cox regression analysis revealed a statistically significant relationship between uNGAL and AKI occurrence. (HR = 1.04 (1.008–1.07), p = 0.01). There was a relation between uNGAL day + 9 to baseline ratio and incidence of AKI (unadjusted HR = 1.047 (1.012–1.083), p < 0.01). The area under the receiver-operating characteristic curve for day + 9 to baseline ratio was 0.86 (0.74–0.99, p < 0.01) and a cut-off value of 2.62 was 85% sensitive and 83% specific in predicting AKI. Our results indicated that increase in uNGAL augmented the risk of AKI and the changes of day +9 uNGAL concentrations from baseline could be of value for predicting AKI in HSCT patients. Additionally uNGAL changes preceded serum Cr raises by nearly 2 days.

25 October 2018 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
AJAmir Jafarian-Amirkhizi
Amir Jafarian-Amirkhizi
ASAmir Sarayani
Amir Sarayani
KGKheirollah Gholami
Kheirollah Gholami
MTMaryam Taghizadeh-Ghehi
Maryam Taghizadeh-Ghehi
KHKazem Heidari
Kazem Heidari
DMDonald Morisky
Donald Morisky

8 April 2014 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
SASara Ataei
Sara Ataei
MHMolouk Hadjibabaie
Molouk Hadjibabaie
AMAmirhossein Moslehi
Amirhossein Moslehi
MTMaryam Taghizadeh-Ghehi
Maryam Taghizadeh-Ghehi
AAAsieh Ashouri
Asieh Ashouri
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh